NovaBay® Pharmaceuticals, Inc. (NYSE: NBY ), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today provided a business update highlighting recent accomplishments and outlook for 2013. Dr. Ron Najafi, Chairman and Chief Executive Officer, said, "2012 was an exciting year